Mineralys (MLYS) Q1 2026 Earnings Call Summary
Mineralys (MLYS) reported Q1 2026 earnings, highlighting the FDA's acceptance of its New Drug Application for lorundrostat with a PDUFA date of December 22, 2026. The company has $646.1 million in cash and cash equivalents as of March 31, 2026, and plans to focus its initial launch on patients with resistant hypertension.
Tickers: $MLYS
Topics: clinical_trials drug_development pharmaceuticals regulatory